Study Finds Telehealth Prescriptions for ADHD Do Not Increase Risk of Substance Use Disorders
A groundbreaking study shows that prescribing ADHD medications via telehealth does not increase the risk of substance use disorders, supporting its safe use for treatment accessibility.
Recent research conducted by Mass General Brigham provides reassurance about the safety of prescribing ADHD medications via telehealth. The study, the first of its kind, compared the rates of substance use disorder among patients with ADHD who received stimulant medications through in-person visits versus virtual appointments during the COVID-19 pandemic. Findings showed that overall, telehealth prescribing was not associated with an increased risk of developing substance use disorders.
The investigation analyzed electronic health records of 7,944 patients between March 2020 and August 2023, a period marked by a significant shift to online healthcare services. It was observed that 91% of these patients had at least one in-person consultation around the time they received a stimulant prescription, while 9% relied solely on telehealth.
Importantly, the study revealed that patients who initially received stimulant prescriptions via telehealth did not exhibit a higher overall risk of substance use disorder compared to those who started with in-person visits, after accounting for variables like age and income. However, more nuanced findings indicated that patients aged 26 and older who received their first stimulant prescription through telehealth might have an elevated risk of developing stimulant use disorder, which involves drugs such as prescription stimulants, cocaine, or methamphetamine.
The researchers emphasized caution, noting that only 19 participants developed stimulant use disorder, making it difficult to draw definitive conclusions. This small number suggests the possibility that these findings could be coincidental or reflect a higher inherent risk among patients opting for telehealth.
Lead author Dr. Vinod Rao explained that the majority of data supports the safety of telehealth for ADHD medication management. Co-author Dr. Timothy Wilens highlighted that this study reinforces the viability of telehealth-based stimulant therapy, helping make treatment more accessible without increasing adverse risks.
Overall, the study advocates for continued use of telehealth in managing ADHD with stimulants, provided there is comprehensive diagnosis and regular follow-up. These findings contribute valuable insight into safe prescribing practices in the evolving landscape of digital healthcare.
Source: MedicalXpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
The Power of Listening in Cardiac Rehabilitation: Enhancing Patient Recovery through Empathy
Effective healing in cardiac rehabilitation relies on empathy and active listening. Understanding patients' social, cultural, and emotional experiences is key to designing personalized recovery programs and improving outcomes.
Federal Move to Decertify Miami-Based Organ Donation Agency Sparks Concerns
Federal health officials are evaluating the shutdown of the Miami-based Life Alliance Organ Recovery Agency due to safety and operational shortcomings, marking a significant step in efforts to improve organ donation systems in the U.S.
Innovative Genetically Engineered Immune Cells Offer Hope for Organ Transplant Rejection Prevention
Researchers develop a targeted immunotherapy using genetically engineered immune cells to prevent organ rejection, offering hope for more precise and effective transplant treatments.
Innovative Scattering Polarimeter Enhances Brain Nerve Fiber Imaging
A new Scattering Polarimeter developed by researchers enhances the imaging of nerve fibers in the brain, offering faster, more accurate insights into neural pathways and brain connectivity. This cutting-edge technology combines existing methods to revolutionize neuroimaging research.